sought in all cases. A significant increase was noted for all high-risk populations and fungal infections were detected in 7% of all (unselected) autopsies in 1992. ' The increase in the number of cases among patients with hematologic malignancies in consolidation or maintenance phase and among those treated with corticosteroids is particularly notable .8,9 The underlying disease or condition greatly determines the level of risk for patients to become infected by Aspergillus species (Table l) ." However, the frequency of cases observed by individual physicians may vary greatly for different patient groups, depending on the risk period. For some patients this is life-long, such as patients with acquired immunodeficiency syndrome (AIDS) or chronic granulomatous disease, whereas in other patient groups, such as those treated for acute myeloid leukemia, the risk period is highest for only several weeks.
Invasive aspergillosis usually affects the lungs, sinuses, or tracheobronchial tree. Pulmonary or sinus disease may be acute or chronic, and the pace with which the disease progresses varies greatly Some patients die within 7 to 10 days of first symptoms or radiologic abnormality; others can present 2 or 3 months after symptoms first appear. The pattern and degree of immunosuppression usually determines the rapidity of the course, so that invasive aspergillosis in corticosteroid-treated and profoundly neutropenic patients progresses more rapidly. A large number of unusual manifestations of invasive aspergillosis continue to be reported, including, for example, postoperative ocular and neurosurgery infections, Aspergillus prostatitis and peritonitis, breast implants and catheter device infections, and infection of the posterior mediastinum and unusual bony sites.11-17 In addition, patients without conventional risk factors, including neonates or patients with systemic lupus erythematosus, or following drowning, or those with multiple myeloma are acquiring the disease.*8-21
The diagnosis of invasive aspergillosis is difficult to establish since specimens for histology and culture, necessary to prove tissue invasion by the fungus, are often difficult to obtain in clinical practice. Although, over a period of 14 years the number of patients diagnosed antemortem increased from 7% to 32%, at present, the majority of Aspergilhs infections still remain undetected during life. 8, 22 Circumstantial evidence of infection can be obtained by culture and cytology of respiratory tract 61 specimens, serology, or imaging techniques. New diagnostic methods presently under investigation include the detection of Aspergillus DNA, or antigens, and high-resolution computed tomography (CT).23~24 The improved sensitivity of these tests and procedures may allow for the early detection of the disease, especially when the methods are combined. A recently published study showed that early thoracic CT scans of febrile neutropenic patients and culture and antigen detection of bronchoalveolar lavage fluid improved the prognosis of invasive aspergillosis when combined with early antifungal therapy and adjuvant thoracic surgery.25 A more aggressive approach to diagnosing fungal infections may be warranted not only to obtain the diagnosis at an early stage of disease but also to identify the pathogen causing disease, since the number of invasive infections by molds other than Aspergillus fumigatus is increasing.* Only 34% of patients who receive treatment for invasive aspergillosis show a favorable response, and the crude mortality is 86/o O .26 Perhaps this high mortality is not surprising, given the difficulties of establishing the diagnosis and the poor therapeutic responsesThe prognosis of invasive aspergillosis is determined by many factors, most importantly, by the response of the underlying disease to therapyThe detection of in vitro and in vivo resistance among A. fumigatus to itraconazole has added to the factors that may reduce the probability of surviving the infection.27,28 Reproducible and meaningful in vitro susceptibility tests need to be developed, to establish the frequency of resistance among A. fumigatus to amphotericin B and itraconazole. These tests may be used to help guide antifungal therapy, since the choice of antifungal agent is often critical in severely immunocompromised patients.
The autopsy performed on the first reported granulocytopenic patient with disseminated invasive aspergiuosis, in 1953, revealed that besides invasive aspergillosis the patient had suffered from a concurrent disseminated infection by Candida species (moniliasis).* Although now, 45 years later, both pathogens still account for the majority of invasive fungal infections, the changes in epidemiology indicate that attempts to control fungal infections have been partially successful for Candida but have thus far failed for AspergiZZus.The increasing number of cases and the high mortality associated with invasive aspergillosis underscores the necessity for further development and evaluation of rapid diagnostic techniques for different patient groups, the development of reproducible and meaningful in vitro susceptibility tests, and randomized studies for prevention of and treatment for invasive aspergillosis.
